HIV Prevention With PrEP Among People on Opioid Replacement Therapy

This study tests whether PrEP (pre-exposure prophylaxis — a daily pill that prevents HIV infection) is effective and accepted among people who are on opioid replacement therapy (such as methadone or buprenorphine) for opioid addiction. People in this group face elevated HIV risk but are often underserved by prevention programs. **You may be eligible if...** - You do not have HIV - You have ongoing behaviors that put you at risk of HIV (as assessed by your clinician) - You are regularly attending your opioid replacement therapy program at least 3 days per week - You are willing to return for follow-up visits **You may NOT be eligible if...** - You have kidney disease or another condition that makes PrEP unsafe - You have taken PrEP in the past 24 hours - You need HIV post-exposure prophylaxis (PEP) at the time of enrollment Talk to your doctor to see if this trial is right for you.